Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 1097, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Astill, M. E.
Right arrow Articles by Nuttall, K. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Astill, M. E.
Right arrow Articles by Nuttall, K. L.
Related Collections
Right arrow Laboratory Management
(Clinical Chemistry. 1997;43:1097.)
© 1997 American Association for Clinical Chemistry, Inc.

Letters

Undisclosed Radioactivity in Specimens: How Much of a Problem?

Mark E. Astill1 and Kern L. Nuttall1,2,a

1 ARUP Labs., 500 Chipeta Way, Salt Lake City, UT 84108
2 Dept. of Pathol., Univ. of Utah School of Med., 50 North Medical Dr., Salt Lake City, UT 84132
a Address correspondence to this author, at ARUP Labs.


To the Editor:

Our institution, a clinical reference laboratory, receives specimens from a wide geographic location. In September 1996, a waste-disposal contractor alerted us to the presence of residual radioactivity in a 30-gallon (~135-L) drum of what was supposed to be nonradioactive laboratory waste. Because clinical laboratories are regulated regarding the receipt, use, and disposal of radioactive material, we sought the source. Investigation revealed that the radiation originated from a urine specimen container, specifically from a specimen sent for catecholamine testing. During an evaluation for a possible pheochromocytoma, the patient involved had undergone nuclear imaging with radiolabeled m-iodobenzyl guanidine (MIBG) before urine collection for biochemical studies (MIBG is often used in nuclear medicine to evaluate suspected pheochromocytomas (1)). The isotope involved was 131I, which has an 8-day . . . [Full Text of this Article]


References






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.